Abstract
Objective: To evaluate the long-term efficacy of triptorelin 3.75 mg subcutaneously every 6 weeks on the final height in girls with idiopathic central precocious puberty (ICPP).
Methods: Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously in our hospital from 2002 to December 2010 and reached their final heights were enrolled. These patients were treated with triptorelin alone (group A, n=17) or triptorelin+recombinant human growth hormone (rhGH) (group B, n=23). Height, weight, annual growth velocity (GV), sexual development, predicted adult height (PAH), and adverse effects were observed. Bone age (BA) and height standard deviation score (SDS) were monitored yearly.
Results: Final adult heights (FAHs) were 159.81±1.20 cm and 161.01±1.02 cm in group A vs. group B, which exceeded target height (THt) by 1.51±1.04 cm, 4.86±0.94 cm, respectively. The values of (FAH-THt), (FAH-PAH posttreatment) showed significant difference between the two groups (p<0.05). FAH was positively correlated with Ht SDS-BA at the end of treatment, THt, course of rhGH treatment, and age of menarche (r2=0.66). Body mass index (BMI) increased after treatment in group B. However, there was no significant tendency of increase compared with healthy children at the same age. Ages of menarche and time to menarche from discontinuation were 11.74±0.16 vs. 12.18±0.15 years and 17.41±1.69 vs. 14.71±1.04 months in two groups.
Conclusion: The FAH was improved effectively by triptorelin 3.75 mg subcutaneously every 6 weeks, and more height gain could be achieved when rhGH was used concomitantly. BMI maintained steadily and ovarian function restored quickly after treatment discontinuation with the age of menarche similar to that of normal children. Neither significant side effect nor polycystic ovary syndrome was observed.
Acknowledgments
We thank Professor Muti Wang (Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) for his guidance, generous assistance, and invaluable advice.
References
1. Herman-Giddens ME, Slora EJ, Wasserman RC, Bourdony CJ, Bhapkar MV, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics 1997;99:505–12.10.1542/peds.99.4.505Search in Google Scholar
2. Ma HM, Du ML, Luo XP, Chen SK, Liu L, et al. Pubertal Study Group of the Society of Pediatric Endocrinology and Genetic Disease, Chinese Medical Association. Onset of breast and pubic hair development and menses in urban Chinese girls. Pediatrics 2009;124:e269–77.10.1542/peds.2008-2638Search in Google Scholar
3. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009; 123:e752–62.10.1542/peds.2008-1783Search in Google Scholar
4. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 2007;92:3483–9.10.1210/jc.2007-0321Search in Google Scholar
5. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, et al. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008;93:190–5.10.1210/jc.2007-1216Search in Google Scholar
6. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001;86:4711–6.10.1210/jcem.86.10.7915Search in Google Scholar
7. Broekmans FJ, Bernardus RE, Berkhout G, Schoemaker J. Pituitary and ovarian suppression after early follicular and mid-luteal administration of a LHRH agonist in a depot formulation: decapeptyl CR. Gynecol Endocrinol 1992;6:153–61.10.3109/09513599209015549Search in Google Scholar
8. Tse CY, Chow AM, Chan SC. Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study. Hong Kong Med J 2000;6:260–4.Search in Google Scholar
9. Filicori M, Cognigni GE, Arnone R, Pocognoli P, Tabarelli C, et al. Subcutaneous administration of a depot gonadotropin-releasing hormone agonist induces profound reproductive axis suppression in women. Fertil Steril 1998;69:443–9.10.1016/S0015-0282(97)00553-0Search in Google Scholar
10. Liang Y, Wei H, Zhang J, Hou L, Luo X. Efficacy ofsubcutaneous administration of gonadotropin-releasing hormone analogs on idiopathic central precocious puberty. J Huazhong Univ Sci Technolog Med Sci 2006;26:436–9.10.1007/s11596-006-0519-2Search in Google Scholar
11. Group of Endocrine and Genetic Metabolic Diseases, Chinese Society of Pediatrics, Chinese Medical Association, et al. Recommendations for the diagnosis and treatment of central precocious puberty. Chin J Pediatr 2003;41:272–3.Search in Google Scholar
12. Zachmann M, Sobradillo B, Frank M, Frisch H, Prader A. Bayley-Pinneau, Roche-Wainer-Thissen, and Tanner height predictions in normal children and in patients with various pathologic conditions. J Pediatr 1978;93:749–5.10.1016/S0022-3476(78)81071-3Search in Google Scholar
13. Kanety H, Karasik A, Pariente C, Kauschansky A. Insulin-like growth factor-I and IGF binding protein-3 remain high after GnRH analogue therapy in girls with central precocious puberty. Clin Endocrinol (Oxf) 1996;45:7–12.10.1111/j.1365-2265.1996.tb02053.xSearch in Google Scholar
14. Weise M, Flor A, Barnes KM, Cutler GB Jr, Baron J. Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty. J Clin Endocrinol Metab 2004;89:103–7.10.1210/jc.2002-021999Search in Google Scholar PubMed
15. Cisternino M, Draghi M, Lauriola S, Scarcella D, Bernasconi S, et al. The acid-labile subunit of human ternary insulin-like growth factor-binding protein complex in girls with central precocious puberty before and during gonadotropin-releasing hormone analog therapy. J Clin Endocrinol Metab 2002;87:4629–33.10.1210/jc.2002-020308Search in Google Scholar PubMed
16. Wit JM, Rekers-Mombarg LT, Dutch Growth Hormone Advisory Group. Final height gain by GH therapy in children with idiopathic short stature is dose dependent. J Clin Endocrinol Metab 2002;87:604–11.10.1210/jcem.87.2.8225Search in Google Scholar PubMed
17. Kirkland JL, Gibbs AR, Kirkland RT, Clayton GW. Height predictions in girls with idiopathic precocious puberty by the Bayley-Pinneau method. Pediatrics 1981;68:251–2.10.1542/peds.68.2.251Search in Google Scholar
18. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Hum Reprod Update 2004;10:135–47.10.1093/humupd/dmh012Search in Google Scholar PubMed
19. Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf) 2004;61:626–34.10.1111/j.1365-2265.2004.02146.xSearch in Google Scholar PubMed
20. Traggiai C, Perucchin PP, Zerbini K, Gastaldi R, De Biasio P, Lorini R. Outcome after depot gonadotrophin-releasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height. Eur J Endocrinol 2005;153:463–4.10.1530/eje.1.01975Search in Google Scholar PubMed
21. Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, et al. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004;150:533–7.10.1530/eje.0.1500533Search in Google Scholar PubMed
22. Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 2010;95:109–17.10.1210/jc.2009-0793Search in Google Scholar PubMed
23. Chiavaroli V, Liberati M, D’Antonio F, Masuccio F, Capanna R, et al. GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome. Eur J Endocrinol 2010;163:55–62.10.1530/EJE-09-1102Search in Google Scholar PubMed
24. Heger S, Müller M, Ranke M, Schwarz HP, Waldhauser F, et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol 2006;254–255:217–20.10.1016/j.mce.2006.04.012Search in Google Scholar PubMed
©2015 by De Gruyter
